GLP-1 Injection Site Reaction: Redness, Bumps, Itching
In this guide
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.
A GLP-1 injection site reaction is redness, itching, a firm bump, bruising, pain or a rash where you injected. The FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro all list injection site reactions, and the reported rates range from under 1% to about 8% of people depending on the medicine. What matters is telling a local reaction apart from a serious allergic reaction, which the labels treat as an emergency. This guide restates what each label says, with its numbers, and when to call someone.
About Dosinha: a shot log, reminders, injection-site rotation, weight and water are free forever. See what is free and what Pro adds.
Key points
- Injection site reactions are listed on all four labels, at rates from 0.2% to 8% in their trials.
- The labels describe redness, itching, bruising, pain, rash, hardness and irritation at the site.
- Swelling of the face, lips, tongue or throat, trouble breathing, or severe rash or itching means get medical help right away.
- The labels do not list a home treatment for a site reaction. Ask your pharmacist or prescriber.
How common GLP-1 injection site reactions are, per label
Each label reports reactions from its own trials, so the numbers are not directly comparable between products. Here is what each one says:
| Product | Reported on the medicine | On placebo | What the label includes |
|---|---|---|---|
| Wegovy injection (adult weight trials) | 1.4% | 1% | Itching, redness, inflammation, hardness (induration), irritation |
| Ozempic (placebo-controlled trials) | 0.2% | Not stated | Discomfort, redness |
| Zepbound (weight trials, by dose) | 6% at 5 mg, 8% at 10 mg, 8% at 15 mg | 2% | Bruising, redness, itching, pain, rash and related terms |
| Mounjaro (adult placebo-controlled trials) | 3.2% | 0.4% | Injection site reactions |
The tirzepatide labels add a detail. In the Zepbound weight trials, site reactions were more frequent in people who developed antibodies to tirzepatide (11.3%) than in those who did not (1%). The Mounjaro label reports a similar pattern: 4.6% with antibodies and 0.7% without. You cannot tell your own antibody status from home, so this is context, not something to act on.
What a site reaction can look like
Based on the terms the labels use, a local reaction can show up as:
- Redness (erythema) around the spot.
- Itching (pruritus).
- A firm or hard area (induration), noted on the Wegovy label.
- Bruising or pain, noted on the Zepbound label.
- A rash at the site, also on the Zepbound label.
A small drop of blood or liquid right after the shot is different. The Zepbound and Mounjaro IFUs call that normal and say to press a cotton ball or gauze on the spot and not to rub.
Rash and allergic reactions are a separate heading
The labels list hypersensitivity (allergic) reactions apart from site reactions, and they take them seriously.
- All four labels say serious allergic reactions, including anaphylaxis and angioedema (swelling under the skin), have been reported.
- The Zepbound label says that in its weight trials, allergic reactions within one day of a dose occurred in 2.1% of people on the medicine and 0.4% on placebo, and that most allergic reactions in its trials were skin reactions such as rash and itching. Severe allergic reactions occurred in 0.1%.
- The Mounjaro label reports allergic reactions in 3.2% of people on the medicine and 1.7% on placebo, sometimes severe, such as hives and eczema.
- The Wegovy label reports rash and hives (urticaria) each in 3% of children 12 and older on the medicine in its pediatric trial, and none on placebo.
Each label lists a previous allergic reaction to the medicine among the reasons not to use it.
People search for “semaglutide rash treatment” and “Ozempic rash treatment.” The labels do not give a home treatment for a rash. They say to stop the medicine and get help right away for signs of a serious allergic reaction, and to talk to your healthcare provider about any side effect that bothers you or does not go away. For a rash that is not an emergency, call your prescriber or pharmacist and let them decide what to do. Ask before you change anything about your shots.
What the IFUs say about choosing and rotating sites
The Instructions for Use do not claim that technique prevents reactions, but they do give site rules:
- The Wegovy IFU says not to inject where the skin is tender, bruised, red or hard, and to avoid scars and stretch marks.
- The Zepbound and Mounjaro pen IFUs say to rotate your site each week. You may use the same body area, but choose a different spot in that area.
- The Ozempic label says to use a different site each week when injecting in the same body region.
That is where a log helps. If you note a reaction, you also know which spot to skip next time. Our pillar guide on injection site rotation and logging has a simple pattern, and how to inject a GLP-1 in the stomach covers the site distances the IFUs give. Your prescriber and pharmacist set your plan.
When to call a clinician
When to call: The Medication Guides for Wegovy, Ozempic, Zepbound and Mounjaro say to stop using the medicine and get medical help right away if you have symptoms of a serious allergic reaction: swelling of the face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or a very rapid heartbeat.
Call your prescriber or pharmacist for a site reaction that bothers you, does not go away, or keeps coming back. Bring a photo and the date of the shot if you can. The guides also say to stop the medicine and call right away for severe stomach pain that will not go away, with or without vomiting.
If your reaction showed up after your first GLP-1 shot, tell your prescriber at your next check-in, or sooner if it worries you.
Frequently asked questions
Is a red bump after a GLP-1 shot normal?
Redness and hardness at the site are among the injection site reactions the labels list. They were reported in a minority of people in the trials. If it bothers you, grows, or does not go away, call your prescriber or pharmacist.
How long does a GLP-1 injection site reaction last?
The labels do not give a typical duration. Tell your healthcare provider about any reaction that does not go away, and get help right away for signs of a serious allergic reaction.
What is the treatment for a semaglutide rash?
The Wegovy and Ozempic labels do not list a home treatment for a rash. They say to stop the medicine and get medical help right away for a severe rash or itching or other signs of a serious allergic reaction. For a milder rash, ask your prescriber or pharmacist.
Are tirzepatide site reactions more common than semaglutide ones?
The reported rates are higher on the Zepbound and Mounjaro labels than on the Wegovy and Ozempic labels, but each comes from different trials, so they cannot be compared directly. Your own experience may differ.
Keep a record of reactions and sites
Dosinha’s rotation body map shows where each shot went and the date. If a site reacts, the side-effect check-in lets you record what you noticed and how strong it felt, so you can show your prescriber the pattern. The shot log, rotation map and check-ins are free. Try the free tools.
Sources
- DailyMed. Wegovy prescribing information, Medication Guide and Instructions for Use, sections 4, 5.7 and 6.1. Novo Nordisk, label revised June 2026.
- DailyMed. Ozempic prescribing information and Medication Guide, sections 2.1, 5.8 and 6.1. Novo Nordisk, label revised June 2026.
- DailyMed. Zepbound prescribing information, Medication Guide and Instructions for Use, sections 5.6 and 6.1, Table 1. Eli Lilly, label revised August 2026.
- DailyMed. Mounjaro prescribing information, Medication Guide and Instructions for Use, sections 5.4 and 6.1. Eli Lilly, label revised August 2026.
This article is for information only and is not medical advice. Talk to your prescriber or a qualified professional.